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Toxoplasma gondii (T. gondii) is an obligate intracellular parasite which can infect
almost all warm-blood animals, leading to toxoplasmosis. Screening and discovery
of an effective vaccine candidate or new drug target is crucial for the control of this
disease. In this study, the recombinant T. gondii elongation factor 1-alpha (rTgEF-1α)
was successfully expressed in in Escherichia coli. Passive immunization of mice with
anti-rTgEF-1α polyclonal antibody following challenge with a lethal dose of tachyzoites
significantly increased the survival time compared with PBS control group. The survival
time of mice challenged with tachyzoites pretreated with anti-rTgEF-1α PcAb also
was significantly increased. Invasion of tachyzoites into mouse macrophages was
significantly inhibited in the anti-rTgEF-1α PcAb pretreated group. Mice vaccinated
with rTgEF-1α induced a high level of specific anti-T. gondii antibodies and production
of IFN-gamma, interleukin-4. The expression levels of MHC-I and MHC-II molecules
as well as the percentages of CD4+ and CD8+ T cells in mice vaccinated with
rTgEF-1α was significantly increased, respectively (P < 0.05), compared with all the
controls. Immunization with rTgEF-1α significantly (P < 0.05) prolonged survival time
(14.53 ± 1.72 days) after challenge infection with the virulent T. gondii RH strain.
These results indicate that T. gondii EF-1α plays an essential role in mediating host
cell invasion by the parasite and, as such, could be a candidate vaccine antigen against
toxoplasmosis.
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INTRODUCTION
Toxoplasma gondii, an obligate intracellular parasite, can infect virtually all warm-blooded
vertebrates including wild mammals, birds, livestock, poultry, and human beings throughout
the world, posing a significant public health concern (Zhao et al., 2012; Dubey et al., 2014;
Zhang et al., 2014). The symptoms of T. gondii infection in humans ranged from asymptomatic
in immunocompetent individuals to devastating in immune-compromised individuals and
unprotected fetuses (Innes, 2010; Luma et al., 2013). Epidemiologic survey results showed that
the high T. gondii prevalence in many economic animals led to considerable economic losses (Kim
et al., 2009; Rassouli et al., 2011; Chessa et al., 2014).
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In general, elongation factor 1-alpha (EF-1α) is highly
conserved and ubiquitously expressed in all eukaryotic cells
(Parkhill et al., 2000; Strausberg et al., 2002; Kristensen et al.,
2005). Functionally, EF-1α transfers aminoacylated tRNAs to
the ribosome A site in a GTP-dependent reaction (Riis et al.,
1990). In addition, EF-1α appears to have a number of other
functions associated with cell growth, motility, protein turnover,
and signal transduction (Ridgley et al., 1996), more recently DNA
replication/repair protein networks (Toueille et al., 2007) and
apoptosis (Lamberti et al., 2007).
EF-1α has been studied in the context of pathogenicity or
virulence for various microbes (Granato et al., 2004; Skarin et al.,
2011; Matsubayashi et al., 2013). In the probiotic bacterium
Lactobacillus johnsonii, the attachment to epithelial cells in
the gastrointestinal tract is mediated by surface-associated EF-
Tu, the prokaryotic homologue to eukaryotic EF-1α (Granato
et al., 2004). The Giardia EF-1α protein localizes to the nuclear
region in trophozoites but it relocalizes to the cytoplasm
during host-cell interaction. It was a member of the excretory-
secretory products of Giardia intestinalis trophozoites, have been
suggested to be important during Giardia infections (Skarin
et al., 2011). Cryptosporidium parvum (C. parvum) EF-1α protein,
which localizes to the apical region of the parasite, mediates
cryptosporidial cytoskeletal complex formation. The anti EF-
1α mAb significantly inhibited in vitro host cell invasion by
C. parvum. These results indicate that C. parvum EF-1α plays
an essential role in mediating host cell entry by the parasite
and, as such, could be a candidate vaccine antigen against
cryptosporidiosis (Matsubayashi et al., 2013).
In this study, the full-length cDNA encoding TgEF-1α was
cloned and expressed in E. coli. The protective efficacy induced
by the recombinant TgEF-1α was evaluated, and the relevant
immuno-mechanisms were investigated. This study provides
the basis for the potential evaluation of TgEF-1α as a vaccine
candidate or drug target against T. gondii infection in the future.
MATERIALS AND METHODS
Ethics Statement
The study was approved by the Animal Care and Use Committee
of Nanjing Agricultural University, in compliance with the
Regulations for the Administration of Affairs Concerning
Experimental Animals (The State Science and Technology
Commission of China, 1988).
Cell Culture, Animals, and Parasite
The Ana-1 mouse macrophage cell line, which were obtained
from the Institute of Cell Biology, Chinese Academy Sciences
(Shanghai, China), were cultured in RPMI 1640 medium
containing 10% heat inactivated fetal bovine serum (FBS),
100U/ml penicillin and 100 mg/ml streptomycin at 37◦C in a 5%
CO2 atmosphere.
Five-week-old female BALB/c mice were purchased from
the Center of Comparative Medicine, Yangzhou University
(Yangzhou, China) and maintained under specific-pathogen-free
standard conditions. All the animal experiments were approved
by the Animal Ethics Committee of Nanjing Agricultural
University (Approval number 200709005). T. gondii RH strain
(Type I) was provided by Laboratory of Veterinary Molecular and
Immunological Parasitology, Nanjing Agricultural University,
China. To maintain the parasite, as described previously (Wang
et al., 2014), BALB/c mice were intraperitoneally (i.p) injected
with the parasite tachyzoites. Every 3 days, the tachyzoites were
harvested and recovered from peritoneal washings of infected
mice to be used for re-infection.
Cloning and Molecular Characterization
of TgEF-1α
According to the manufacturer’s protocol, Trizol reagent (Takara,
Dalian, China), was used to extract total RNA from the
tachyzoites of T. gondii RH strain and the cDNA was constructed.
Primers were designed according to the nucleotide sequences of
the clone T. gondii elongation factor 1-alpha (GenBank accession
no. XM_002370208.1). The forward and reverse primers,
5′- CGCGGATCC ATGGGTAAGGAAAAGACTCACATTAAC-
3′ and 5′- CCGCTCGAGCGAAGCG GTAGATTTGTTCCAAT-
3′, were used to amplify the complete open reading frame (ORF)
of TgEF-1α using the cDNA of T. gondii RH tachyzoites as a
template. The underlined sequences represent the sites of BamHI
and XhoI (Takara, Dalian, China), respectively. The PCR product
was subcloned into the pMD19-T vector (Takara, Dalian, China)
according to the manufacturer’s instructions and positive clones
were selected for sequencing.
Expression and Purification of
Recombinant TgEF-1α (rTgEF-1α)
The cloned gene fragments were excised by dual BamHI/XhoI
digestion and subcloned into the pET-32a (+) vectors (Novagen,
USA) at the unique BamHI/XhoI site. The rTgEF-1α was
expressed in the E. coli BL21(DE3) strain and purified by
nickel-affinity chromatography according to the manufacturer’s
instructions (Novagen, USA). The purity of the eluted protein
was analyzed by 12% SDS-PAGE electrophoresis and Coomassie
blue staining. Before mouse or rat immunization, rTgEF-1α was
dialyzed against PBS (pH 7.2) and the purified protein was
quantified with the Easy Protein Quantitative Kit (TransGen
Biotech, Beijing, China).
Production of Polyclonal Antibodies
Against rTgEF-1α
To generate polyclonal antibodies against rTgEF-1α, SD rats were
immunized subcutaneously with either 200 µg of recombinant
TgEF-1α protein or PBS (control) emulsified with an equal
volume of Freund’s complete adjuvant (Sigma–Aldrich, UK).
Two weeks later, booster immunizations were done using either
200 µg of recombinant TgEF-1α protein or PBS emulsified
with incomplete Freund’s adjuvant (Sigma–Aldrich, UK). Second
booster immunizations were done 2 weeks later. Ten days after
the second booster immunizations, rats were sacrificed and blood
collected by cardiac puncture. Sera were extracted and affinity
purified to monospecificity by affinity column chromatography
as previously described (Witola et al., 2006).
Frontiers in Microbiology | www.frontiersin.org 2 February 2017 | Volume 8 | Article 168
fmicb-08-00168 February 13, 2017 Time: 12:11 # 3
Wang et al. TgEF-1α is a Potential Protective Antigen of T. gondii
Western Blot Analysis of rTgEF-1α and
Native TgEF-1α
Analysis of rTgEF-1α
Purified rTgEF-1α was mixed with SDS loading buffer and
electrophoresed on 12% SDS-PAGE gel and electro-transferred
to PVDF (Immobilon, Millipore, USA) with a Trans-Blot SD
system (Bio-Rad). Non-specific binding sites were blocked
by immersing the membranes in blocking buffer (5% skim
milk in Tris-buffered saline containing 0.1% Tween-20) for
2 h at 37◦C. The membranes were then washed five times
(5 min each) in Tris-buffered saline containing 0.1% Tween-
20 (TBST). Subsequently, the membranes were incubated with
the primary antibody (antiserum from chickens experimentally
infected with T. gondii) overnight at 4◦C (dilutions 1:100 in
TBST). After being washed five times in TBST, the membranes
were then incubated with HRP-conjugated goat anti-chicken
IgG (SouthernBiotech,USA) for 1 h at 37◦C (diluted 1:6000 in
TBST). Finally, the immunoreaction was visualized using freshly
prepared diaminobenzidine (DAB, Sigma) as a chromogenic
substrate after 5 min.
Detection of Native TgEF-1α
Toxoplasma gondii lysates were prepared as previously described
(Hassan et al., 2014b), with minor modifications regarding this
current experiment. Briefly, tachyzoites of T. gondii RH strain
were obtained from the peritoneal washings of infected mice.
The exudates were passed twice through a 27-gage needle and
then through 5 µm filter membranes to remove debris and host
cells. Parasites were then washed, re-suspended in phosphate-
buffered saline (pH 7.4), and disrupted by sonication on ice. The
lysates were electrophoresed in 12% SDS-PAGE gel and western
blot analysis was performed as described in Section “Analysis of
rTgEF-1”, using rat anti-rTgEF-1α polyclonal antibodies as the
primary antibody and goat anti-rat IgG (SouthernBiotech, USA)
as the secondary antibody.
Passive Immunization of Mice
Mice (10 mice per group) received an intraperitoneally injection
of 200 µl of the purified anti-rTgEF-1α PcAb with different
concentrations (100, 200, or 500 µg/ml), or rat normal serum,
or PBS alone was considerd as control. All mice were immunized
intraperitoneally twice a week, total four times. Seven days after
the last immunization, mice were infected intraperitoneally with
1 × 104 RH strain tachyzoites. The day of infection was referred
to as day 0, and the survival periods were recorded daily until all
mice were dead.
Pretreatment of T. gondii Tachyzoites
with Anti-rTgEF-1α Polyclonal Antibodies
Toxoplasma gondii tachyzoites were suspended at a concentration
of 4 × 107/ml in RPMI 1640 containing 10% fetal bovine serum
(FBS) and antibiotics. Aliquots of 100µl tachyzoites were mixed
with 100 µl of the purified anti-rTgEF-1α PcAb with different
concentrations (100, 200 or 500 µg/ml), or rat normal serum, or
RPMI 1640 alone, respectively, and incubated at 37◦C for 30 min
on a platform rocker at 10 rpm. After incubation, the parasites
were collected and suspended to 1 ml with RPMI 1640 medium
without FBS.
Pretreated Tachyzoite Challenge of Mice
Mice were challenged by intraperitoneal injection of 1 × 104
RH strain tachyzoites, which were pretreated with either purified
anti-rTgEF-1α PcAb, rat normal serum or RPMI 1640. The day of
infection was referred to as day 0, and the survival periods were
recorded daily until all mice were dead.
Pretreated Tachyzoite Challenge of Macrophage
Monolayers
Macrophage monolayers on coverslips were infected with
pretreated tachyzoites (macrophage: tachyzoite = 1:5), and
incubated for 4 h at 5% CO2 and 37◦C. After 4 h, the cells
were rinsed with HBSS to remove non-ingested parasites and
added complete culture medium to the cells. The coverslips were
then incubated for another 24 h at 5% CO2 and 37◦C, and then
fixed in methanol, and stained with Giemsa to determine the
number of infected cells per 100 macrophages and number of
tachyzoites/100 macrophage on light microscope.
Evaluating the Protective Efficacy of
Recombinant TgEF-1α
Mouse Vaccination and Challenge
A total of 120 BALB/c mice were randomly divided into four
groups (30/group), and each mouse per group subcutaneously
injected with either 100 µg of recombinant protein TgEF-
1α mixed with Freund adjuvant (1:1), Freund adjuvant alone,
or PBS only, respectively, and one group of mice was not
inoculated, which served as a blank control. All groups were
vaccinated three times at weeks 0, 2, and 4, respectively (the
first time with Freund’s complete adjuvant and the other
times with Freund’s incomplete adjuvant). The blood of mice
in each group was collected on weeks 0, 2, 4 and 6 and
the sera were stored at −20◦C for antibodies evaluation and
cytokine measurement. Two weeks after the last vaccination,
the mice in the four groups were challenged intraperitoneally
with 1 × 104 tachyzoites of T. gondii RH strain. The survival
time of the mice were observed and recorded on a daily
basis.
Determination of Antibodies by enzyme-linked
immunosorbent assays (ELISA)
The levels of antibodies in mouse sera were determined by
enzyme-linked immunosorbent assays (ELISA) as previously
described (Hassan et al., 2014a). In brief, the microtiter plates
(Costar, USA) were coated with 1 µg soluble tachyzoite antigens
(STAg) in 50 mM carbonate buffer (pH 9.6) and incubated
at 4◦C overnight. After three washes, the plates were blocked
with 3% Bovine Serum Albumin (BSA) for 2 h at 37◦C and
subsequently incubated with the mouse sera diluted 1:10 in PBS
for 1 h at 37◦C. HRP-conjugated goat anti-mouse IgG, IgG1,
IgG2a, IgA, IgM, and IgE, (SouthernBiotech, USA) were used
as the secondary antibody to detect bound antibodies. Finally,
the immune complexes were developed by incubating with
3,3,5,5-tetramethylbenzidine (TMB) for 20 min. The reaction
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was stopped by adding 2 M H2SO4, and the absorbance
was measured at 450 nm with an automated ELISA reader
(MULTISKAN FC, Thermo scientific), all samples were run in
triplicate.
Cytokine Assays
To assay cytokine production levels, sera from each experimental
group were obtained as described previously. Interferon gamma
(IFN-γ), interleukin-4 (IL-4), interleukin-17 (IL-17), and
transformation growth factor-β1 (TGF-β1) were measured using
ready ELISA kits according to the manufacturer’s instructions
(Boster Systems, Wuhan, China). Cytokine concentrations were
determined by reference to standard curves constructed with
known amounts of mouse recombinant IL-4, IL-17, IFN-γ, and
TGF-β1. The analysis was performed with the data from three
independent experiments.
Flow Cytometry Analysis of T Cell Subsets and MHC
Molecules
The percentages of T cells subsets CD4+ and CD8+, beside
MHC-I and MHC-II molecules in the splenocytes of mice
in the test groups, rTgEF-1α, adjuvant, PBS, and blank,
were determined using flow cytometry technique as described
previously (Sasai et al., 2000). Splenocytes suspensions (1 × 106
cells/ml) were dually stained with anti-mouse CD3e-FITC+anti-
mouse CD8-PE, anti-mouse CD3e-FITC+anti- mouse CD4-PE,
anti-mouse CD3e-FITC+anti-mouse MHC-I-PE or anti-mouse
CD3e-FITC+anti- mouse MHC-II-PE (eBioscience) for 30min
at 4◦C in the dark. Cell population analysis was conducted
by FACScan flow cytometer with CellQuest software (BD
Biosciences, Franklin Lakes, NJ, USA). A lymphocyte specific
gating was set according to forward and side scatters profiles.
The percentages of CD4+ and CD8+ T lymphocytes, MHC-I
and MHC-II molecules in mice splenocytes were determined as
described by Song et al. (2010).
Statistical Analysis
All statistical analyses were performed by IBM SPSS 20.0 Data
Editor (SPSS Inc., Chicago, IL, USA). The differences of the data
(e.g., antibody responses, cytokine production) between all the
groups were compared by one-way ANOVA. Survival time for
the mice were compared using the Kaplan–Meier method. The
results in comparisons between groups were considered different
if the P-value was less than 0.05.
RESULTS
Cloning, Expression, and Purification of
Recombinant TgEF-1α
The ORF of TgEF-1α was 1347 bp encoding a protein of 448
amino acids with a predicted molecular weight of 49.04 kDa and
an isoelectric point of 8.57.
Most of the recombinant TgEF-1α was expressed in E. coli
as a soluble His-tagged fusion protein when bacterial growth
occurred at 37◦C. The soluble recombinant protein was purified
by Niaffinity chromatography. SDS-PAGE analysis revealed that
FIGURE 1 | SDS-PAGE analysis of the purification of recombinant
TgEF-1α. M: protein molecular weight marker; 1: rTgEF-1α purified through
Ni2+-charged column chromatography and after dialysis.
the recombinant protein rTgEF-1α had a molecular weight of
approximately 64 kDa (Figure 1).
Western Blot
Chicken anti-T. gondii antibodies were used to detected the
fusion protein (Figure 2A), while a negative control experiment
was also carried out using sera collected from PBS immunization
group, and no specific band was detected (Figure 2A). The native
TgEF-1α protein in lysates of T. gondii tachyzoites was also
detected using anti-rTgEF-1α polyclonal antibodies showing a
specific band (Figure 2B).
Passive Immunization with
Anti-rTgEF-1α PcAb Significantly
Increased the Survival of Mice
Mice of PBS control group survived 6.33 ± 0.61 days after lethal
tachyzoite challenge. As shown in Table 1, mice immunized
with anti-rTgEF-1α PcAb survived significantly longer compared
to the PBS control group (500 µg/ml, p = 0.001; 200 µg/ml,
p = 0.001; 100 µg/ml, p = 0.024), while anti-rTgEF-1α PcAb
(100 µg/ml) immunized mice had the longest survival time
(9.46± 3.99 days).
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FIGURE 2 | Immunoblot for the recombinant TgEF-1α and native
protein of TgEF-1α. Lane M: standard protein molecular weight marker; (A)
lane 1: Rrecombinant protein TgEF-1α probed by serum from chickens
experimentally infected with Toxoplasma gondii as primary antibody; lane 2:
Rrecombinant protein TgEF-1α probed by serum of normal chickens as
primary antibody. (B) Lane 1: Sonatic extract of T. gondii tachyzoites probed
by rat anti-rEF-1α antisera as primary antibody; lane 2: Sonatic extract of
T. gondii tachyzoites probed by serum of normal rat as primary antibody.
TABLE 1 | Survival days of BALB/c mice challenged intraperitoneally with
lethal doses of tachyzoites after passive immunization with anti-rTgEF-1α
antibodies.
Group Survival daysa p-valueb Survival rate (%)
PBS control 6.33 ± 0.61 – 0
Serum control 6.70 ± 0.48 0.155 0
Anti- rTgEF-1α-A 8.56 ± 1.53 0.001 0
Anti- rTgEF-1α-B 8.80 ± 1.75 0.001 0
Anti- rTgEF-1α-C 9.46 ± 3.99 0.024 10
Anti- rTgEF-1α-A: mice received i.p. injection of 200 µl of the purified anti-rTgEF-
1α PcAb (500 µg/ml); Anti- rTgEF-1α-B: mice received i.p. injection of 200 µl of
the purified anti-rTgEF-1α PcAb (200 µg/ml); Anti- rTgEF-1α-C: mice received i.p.
injection of 200 µl of the purified anti-rTgEF-1α PcAb (100 µg/ml);
aMice were observed 20 days. The data are presented as the mean ± SD of three
separate experiments.
bCompared to the survival time of PBS control group.
Immunization with Tachyzoites
Pretreated with Anti-rTgEF-1α PcAb
Significantly Increased the Survival of
Mice
Toxoplasma gondii tachyzoites were pretreated with anti-rTgEF-
1α PcAb following the protocol, and were then injected into
mice. As shown in Table 2, the survival time of the RPMI
1640 control and serum control group were 6.33 ± 0.61 and
TABLE 2 | Survival days of BALB/c mice challenged intraperitoneally with
lethal doses of tachyzoites pretreated with anti-rTgEF-1α antibodies.
Group Survival daysa p-valueb Survival rate (%)
RPMI 1640 control 6.33 ± 0.61 – 0
Serum control 6.53 ± 0.63 0.483 0
Anti-rTgEF-1α-A 7.30 ± 1.47 0.071 0
Anti-rTgEF-1α-B 9.66 ± 3.93 0.016 10
Anti-rTgEF-1α-C 8.53 ± 1.78 0.009 0
Anti- rTgEF-1α-A: mice received i.p. injection of T. gondii tachyzoites pretreated
with anti-rTgEF-1α PcAb (500 µg/ml); Anti- rTgEF-1α-B: mice received i.p. injection
of T. gondii tachyzoites pretreated with anti-rTgEF-1α PcAb (200 µg/ml); Anti-
rTgEF-1α-C: mice received i.p. injection of T. gondii tachyzoites pretreated with
anti-rTgEF-1α PcAb (100 µg/ml);
aMice were observed 20 days. The data are presented as the mean ± SD of three
separate experiments.
bCompared to the survival time of RPMI 1640 control group.
6.53 ± 0.63 days, respectively. Mice that received anti-rTgEF-
1α PcAb (200 µg/ml and 100 µg/ml) pretreated tachyzoites
survived significantly longer than those that received RPMI 1640
(p < 0.05), control serum pretreated tachyzoites (p < 0.05).
However, pretreatment with anti-rTgEF-1α PcAb (500 µg/ml)
did not produce significantly longer survival times than RPMI
1640 (p> 0.05) and serum control group (p> 0.05).
Anti-rTgEF-1α PcAb Pretreatment
Inhibited Parasite Invasion in
Macrophages
The percentage of infected Ana-1 macrophages in RPMI 1640
control was 63.33 ± 8.62%. There were slightly decreased the
mean percentage of infected macrophages after pretreatment
with control serum (p> 0.05). As shown in Table 3, pretreatment
of tachyzoites with anti-rTgEF-1α PcAb significantly inhibited
parasite invasion in macrophages compared to the a RPMI 1640
control group (63.33 ± 8.62 vs. 36.33 ± 6.81 in 500 µg/ml
anti-rTgEF-1α group, p < 0.05; 63.33 ± 8.62 vs. 34.67 ± 5.51
in 200 µg/ml anti-rTgEF-1α group, p < 0.01; 63.33 ± 8.62 vs.
35.67 ± 5.69 in 100 µg/ml anti-rTgEF-1α group, p < 0.05).
TABLE 3 | Macrophage invasion and multiplication of tachyzoites after
infection by T. gondii pretreated with anti-rTgEF-1α antibodies.
Group No.of infected
cells/100 Mac
p-
valuea
No. of
tachyzoites/
cell
p-
valueb
RPMI 1640 control 63.33 ± 8.62 – 6.70 ± 0.36 –
Serum control 57.00 ± 4.58 0.324 5.93 ± 0.42 0.073
Anti-rTgEF-1α-A 36.33 ± 6.811 0.013 4.83 ± 0.38 0.003
Anti-rTgEF-1α-B 34.67 ± 5.51 0.008 4.77 ± 0.46 0.005
Anti-rTgEF-1α-C 35.67 ± 5.69 0.010 4.73 ± 0.40 0.003
Anti- rTgEF-1α-A: macrophage received T. gondii tachyzoites pretreated with anti-
rTgEF-1α PcAb (500 µg/ml); Anti- rTgEF-1α-B: macrophage received T. gondii
tachyzoites pretreated with anti-rTgEF-1α PcAb (200 µg/ml); Anti- rTgEF-1α-C:
macrophage received T. gondii tachyzoites pretreated with anti-rTgEF-1α PcAb
(100 µg/ml);
aCompared to the RPMI 1640 control group.
bCompared to the RPMI 1640 control group.
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Similarly, there were significant differences in the number of
intracellular parasites per macrophage between PcAb treated and
untreated groups (p< 0.01).
Humoral Immune Responses Induced by
Vaccination
To detect the levels of anti-T. gondii antibodies, all sera were
tested by ELISA. As shown in Figure 3A, a significantly higher
levels of IgG antibodies were detected in the sera of mice
immunized with rTgEF-1a (P < 0.01) versus control groups and
the levels of antibodies increased with successive immunizations.
As expected, no augmentation in antibody levels was detected
in the control mice (Figure 3A). Moreover, both IgG1 and
IgG2a were found in the sera of mice vaccinated with rTgEF-
1a, which showed a mixed anti-T. gondii IgG1/IgG2a profile
(Figures 3B,C). A predominance of IgG2a over IgG1 was
observed in the sera of mice immunized with rTgEF-1a, which
indicated a shift toward the Th1 type response.
In comparison to the control groups, dynamics of the
IgA demonstrated high OD values (P < 0.01) in the
immunized group (0.473 ± 0.093) at two weeks after last
immunization (Figure 3D). However, IgM and IgE activity
showed no significant changes at the time of evaluation
(Figures 3E,F).
Cytokine Measurement
Significantly higher levels of IFN-γ were produced in the sera
of mice immunized with rTgEF-1α compared with the three
control groups (P < 0.01, Figure 4A). On the other hand, low
levels of IL-4 were detected in the groups of mice immunized
with rTgEF-1α, which showed a slight but significant difference
(P< 0.05) compared with mice immunized with the three control
groups (Figure 4B). As for IL-17 and TGF-β1, both of them
displayed no significant changes at similar times of evaluation
(Figures 4C,D).
Evalution of the Percentages of CD4+
and CD8+ T Lymphocytes and MHC
Molecule Changes
The percentage of CD4+ lymphocyte were found to be increased
significantly in the spleen lymphocytes of mice immunized
with rTgEF-1a at week 2, 4, and 6 when compared with with
mice immunized with the three control groups (P < 0.01).
The percentage of CD8+ lymphocyte also were found to
be increased significantly in the spleen lymphocytes of mice
immunized with rTgEF-1a at week 4 and 6 when compared
with mice immunized with the three control groups (P < 0.05,
Table 4).
After the last immunization, MHC-I molecules of immunized
group showed high significant readings (30.47 ± 3.15), in
contrast to adjuvant (18.34 ± 2.40), PBS (17.76 ± 1.16), and
blank (17.88 ± 1.78) groups. Concerning MHC-II molecules, an
increasing pattern was noticed in the vaccinated group starting at
week 4 of the experiment and reaching a peak point (7.96± 1.37)
at week 6 of the experiment (Table 5).
Protective Efficacy of rTgEF-1a in
BALB/c Mice
Survival curves for the four groups of mice are shown in Figure 5.
No differences were observed among the three control groups, all
of the mice in control groups died within 8 days post-challenge.
Mice immunized with rTgEF-1a showed a prolonged survival
time (14.53± 1.72 days; P < 0.01) compared to the three control
groups.
DISCUSSION
In this study, we compared the protective effect of passive
immunization with PcAbs to TgEF-1a at different concentrations.
FIGURE 3 | The dynamics of specific antibody level in BALB/c mice induced by rTgEF-1α vaccination. (A) Determination of IgG antibodies in the sera of
BALB/c mice immunized with rTgEF-1α, Adjuvant, PBS and Blank controls on weeks 0, 2, 4, 6. Determination of IgG subclass (B) IgG1 and (C) IgG2a, (D) levels of
class IgA, (E) levels of class IgM, and (F) levels of class IgE in the sera of the immunized BALB/c mice 2 weeks after the last immunization. Results are expressed as
mean of the OD450 ± SD (n = 5) and statistically significant difference (∗P < 0.05) and (∗∗P < 0.01).
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FIGURE 4 | The dynamics of cytokine production in BALB/c mice induced by rTgEF-1α vaccination. Antibody-captured ELISA was used to determine the
production levels of (A) IFN-γ, (B) IL-4, (C) IL-17, and (D) TGF-β1, in sera samples (n = 5) collected at weeks 0, 2, 4, and 6, and the comparison results were
expressed as means ± SD of pg/ml. The asterisk designates statistically significant differences (∗p < 0.05; ∗∗p < 0.01) between groups. Results presented here
were from three independent experiments.
The period of survival days was significantly increased in mice
passively immunization with PcAb to TgEF-1a compared to
the serum and PBS control group. Similarly, mice immunized
with anti-SAG1 mAb, anti-GRA2 mAb, or anti-GRA6 mAb
survived longer than mice treated with control ascites (Mineo
and Kasper, 1994; Cha et al., 2001; Fu et al., 2011). Another
passive immunization experiment using monoclonal antibodies
against nucleoside triphosphate hydrolase-II (NTPase-II) showed
no inhibition of parasite invasion, but a significant reduction in
T. gondii replication and promoted prolonged survival in mice
after a lethal challenge (Tan et al., 2010). From these results,
it appears that PcAb to TgEF-1a protein, as well as mAbs to
NTPase-II, SAG1 or GRA proteins of T. gondii, are capable of
providing protection in the absence of an already developed
cell-mediated immunity.
Interesting, mice survived better when immunized passively
with lower antibody concentration. In addition, Mice that
received anti-rTgEF-1α PcAb (200 µg/ml or 100 µg/ml)
pretreated tachyzoites survived better than that received
tachyzoites pretreated with anti-rTgEF-1α PcAb (500 µg/ml).
The reason should be further studied.
Host cell invasion by tachyzoites plays a crucial role in
maintaining T. gondii infection. Many factors involved in host
cell invasion or intracellular multiplication had been reported
(Mineo and Kasper, 1994; Huynh and Carruthers, 2006; Dunn
et al., 2008; Beck et al., 2013; Huynh et al., 2014). In this
TABLE 4 | Flow cytometry analysis of the percentages of T lymphocyte subsets.
Marker (%) Time point Groups (n = 5)
Blank PBS Adjuvant rTgEF-1α
CD4+ Week 0 18.01 ± 2.95 18.53 ± 2.76 18.15 ± 2.71 18.18 ± 2.36
Week 2 18.41 ± 1.85 18.55 ± 1.96 18.30 ± 2.78 25.14 ± 2.87∗∗
Week 4 18.03 ± 2.84 18.80 ± 2.88 18.24 ± 1.93 28.27 ± 2.98∗∗
Week 6 18.17 ± 1.54 17.93 ± 2.31 18.68 ± 2.62 30.46 ± 3.43∗∗
CD8+ Week 0 8.20 ± 1.55 8.13 ± 1.28 8.29 ± 1.63 8.36 ± 1.76
Week 2 8.32 ± 1.94 8.00 ± 1.48 8.54 ± 1.15 9.17 ± 1.84
Week 4 8.37 ± 2.07 8.13 ± 1.58 8.45 ± 1.89 11.53 ± 2.91∗
Week 6 8.11 ± 1.12 8.01 ± 1.54 8.24 ± 1.57 12.36 ± 1.47∗∗
Data are presented as the mean ± SD (n = 5).
∗∗represents statistically highly significant difference (P < 0.01) as compared with control groups: Blank (unvaccinated control), PBS and Adjuvant group.
∗represents statistically highly significant difference (P < 0.05) as compared with control groups: Blank (unvaccinated control), PBS and Adjuvant group.
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TABLE 5 | Dynamics of MHC-I and MHC-II molecules in spleen lymphocytes.
Marker (%) Time point Groups (n = 5)
Blank PBS Adjuvant rTgEF-1α
MHC-I Week 0 18.19 ± 2.46 17.17 ± 2.62 18.06 ± 1.54 18.01 ± 2.23
Week 2 16.55 ± 2.15 17.13 ± 1.91 18.17 ± 2.31 24.28 ± 3.29∗∗
Week 4 17.64 ± 1.82 18.02 ± 1.91 18.22 ± 1.76 29.16 ± 3.43∗∗
Week 6 17.88 ± 1.78 17.76 ± 1.16 18.34 ± 2.40 30.47 ± 3.15∗∗
MHC-II Week 0 3.07 ± 0.97 2.88 ± 0.37 3.22 ± 0.62 3.16 ± 0.54
Week 2 2.99 ± 0.71 3.17 ± 0.38 3.13 ± 0.79 3.44 ± 0.96
Week 4 3.25 ± 0.45 3.17 ± 0.38 3.04 ± 0.46 6.78 ± 1.48∗∗
Week 6 3.22 ± 0.56 3.11 ± 0.73 3.05 ± 0.61 7.96 ± 1.37∗∗
Data are presented as the mean ± SD (n = 5).
∗∗represents statistically highly significant difference (P < 0.01) as compared with control groups: Blank (unvaccinated control), PBS and Adjuvant group.
FIGURE 5 | Survival curve of mice after challenge infection with
T. gondii RH strain. Mice were challenged with 104 tachyozoites of the RH
strain intraperitoneally two weeks after the third immunization.
study, we directly evaluated the inhibitory effect of cell invasion
by anti-TgEF-1a PcAb using mouse macrophages. Anti-TgEF-
1a PcAb pretreated tachyzoites exhibited inhibition of parasite
invasion into mouse macrophage compared to the control
groups. Additionly, mice that received anti-rTgEF-1α PcAb
(200 µg/ml and 100 µg/ml) pretreated tachyzoites survived
significantly longer than those that received RPMI 1640, control
serum pretreated tachyzoites (p < 0.05). Taken together, anti-
TgEF-1a PcAb could inhibit the parasite invasion into mouse
macrophage cell line as well as mouse model. These results
indicated that TgEF-1α played an essential role in mediating host
cell invasion. Further analysis is needed to clarify the molecular
role of TgEF-1α during parasite attachment and invasion of host
cells.
The critical role of antibody in immunity to T. gondii has been
recognized for a long time, referred to the ability of killing the
parasite by the attachment of the parasite to the host cell receptors
or resulting from the bindings to the complement protein (Correa
et al., 2007). The mice immunized with rTgEF-1α developed
higher levels of T. gondii-specific IgG antibodies compared to
mice of control groups. Meanwhile, vaccination with rTgEF-1α
exhibited a mixed Th1/Th2 response, with a predominance of
IgG2a (Th1) over IgG1 (Th2). Many studies demonstrated that
a Th1-biased response is required for effective protection against
naturally occurring T. gondii infections (Sayles et al., 2000).
In our study, high titers of IgA were detected in the sera
of rTgEF-1α immunized group, indicating that rTgEF-1α has
successfully induced the release of this antibody as part of the
response generated after immunization. Immunoglobulins IgM
and IgE aslo were reported to participate in the immunological
responses against T. gondii infection (Gomez-Marin et al., 2000;
Lynch et al., 2011; Vouldoukis et al., 2011; Amin et al., 2012).
However, our data revealed no significant changes of these two
immunoglobulin after vaccination with rTgEF-1α.
During natural T. gondii invasion, the generation of strong
cellular immune responses determines the course of the infection
(Dupont et al., 2012; Hotop et al., 2014). In contrast to three
control groups, immunization with rTgEF-1α enhanced the Th1
mediated immunity with high levels of IFN-γ. The cytokine IL-
4 is associated with Th2-type responses, and a slight increase
in the release of IL-4 was also observed in the present study.
Therefore, these findings indicated that specific Th1-type cell
immune response was mainly activated after immunization with
rTgEF-1α.
Due to the obligate intracellular life style, T cell mediated
adaptive immune responses involving in CD4+ and CD8+ T
cells are known to be important in resistance against primary
T. gondii infection and reactivation of chronic toxoplasmosis
(Kugler et al., 2013; Dupont et al., 2014). In the present study, we
observed the increase of both the percentage of CD4+ and CD8+
T cells in mice immunized with rTgEF-1α, which suggested
the activation of CD4+ and CD8+ T cells, and thus may be
in synergy to contribute to cytotoxic activity against T. gondii.
Meanwhile, the significant increase of the MHC class I and MHC
class II molecules was also found in the rTgEF-1α vaccinated
group, suggesting that both the exogenous (MHC class II
restricted) and the endogenous (MHC class I restricted) antigen
presentation pathways were simultaneously activated. The MHC
class I restricted presentation results in a strong CD8+ T cell
mediated immune responses, which enhance the cytoloxicity
against cells infected with T. gondii. The up-regulated MHC-
II molecules could present more T. gondii-derived antigenic
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peptides to CD4+ T cells and induce more strong immune
responses during T. gondii infection, leading to inhibition of the
parasite (Dupont et al., 2014). Take together, the results of the
rTgEF-1α immunization experiments show that the rTgEF-1α
can induce strong humoral and cellular immune responses.
Two weeks after the last immunization with rTgEF-1α,
lethal challenge experiments showed that rTgEF-1α could
prolong survival time in BALB/c mice challenged with
T. gondii tachyzoites (RH strain) when compared with
control groups. However, all mice in our experiment were
dead after challenged with tachyzoites. The current results
indicated that the rTgEF-1α can only induce partial protection
against infection with high virulent T. gondii strain but not
complete, which was similar to the effect of other single gene
subunit vaccines in mice (Huang et al., 2012; Zheng et al.,
2013).
In conclusion, the present study demonstrated, for the first
time, that TgEF-1α plays an essential role in mediating host
cell entry by the parasite, and that TgEF-1α induce a strong
protective humoral and cellular response against T. gondii
infection, which indicated that it is a potential candidate vaccine
antigen against toxoplasmosis. The strategy of using TgEF-1α
protein combined with other antigens appears to be a promising
approach to develop a new subunit multi-component vaccine
against toxoplasmosis.
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